- Published at
- by gurufocus.com
mixed
mixed
News for Theravance Biopharma, Inc. (TBPH)
- Published at
- by gurufocus.com
mixedmixedTheravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results
PR NewswireDUBLIN, Feb. 26, 2025 YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238- Published at
- by gurufocus.com
positivepositiveEarnings To Watch: Theravance Biopharma Inc (TBPH) Reports Q4 2024 Result
Theravance Biopharma Inc (TBPH) is set to release its Q4 2024 earnings on Feb 26, 2025. The consensus estimate for Q4 2024 revenue is $17.09 million, and the ea- Published at
- by gurufocus.com
positivepositiveMadison Avenue Partners, LP Reduces Stake in Ovid Therapeutics Inc
Madison Avenue Partners, LP (Trades, Portfolio), a prominent investment firm, recently executed a significant transaction involving Ovid Therapeutics Inc. On De- Published at
- by gurufocus.com
positivepositiveNewtyn Management, LLC Increases Stake in Theravance Biopharma Inc
On December 31, 2024, Newtyn Management, LLC (Trades, Portfolio), a prominent investment firm, expanded its holdings in Theravance Biopharma Inc by acquiring an- Published at
- by gurufocus.com
positivepositiveWeiss Asset Management LP Acquires Shares in Coincheck Group NV
On December 31, 2024, Weiss Asset Management LP (Trades, Portfolio) made a strategic move by acquiring 220,001 shares of Coincheck Group NV at a price of $8.89- Published at
- by gurufocus.com
positivepositiveTheravance Biopharma to Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025
PR NewswireDUBLIN, Ireland, Feb. 12, 2025 DUBLIN, Ireland, Feb. 12, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its fourth q- Published at
- by manilatimes.net
mixedmixed- Published at
- by markets.businessinsider.com
mixedmixedLycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting ...- Published at
- by investing.com
positivepositiveTheravance biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com
Theravance biopharma SVP Rhonda Farnum sells $36,000 in shares- Published at
- by investing.com
positivepositiveKBR stock rises following WSJ report of activist stake By Investing.com
KBR stock rises following WSJ report of activist stake- Published at
- by gurufocus.com
positivepositiveTheravance Biopharma to Participate in an Upcoming Investor Conference
PR NewswireDUBLIN, Nov. 20, 2024 DUBLIN, Nov. 20, 2024 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) will participate in a Fireside Chat at the- Published at
- by investing.com
positivepositiveTheravance Biopharma SVP Rhonda Farnum sells $36,000 in shares By Investing.com
Theravance Biopharma SVP Rhonda Farnum sells $36,000 in shares- Published at
- by seekingalpha.com
positivepositiveTheravance Biopharma, Inc. (TBPH) Q3 2024 Earnings Call Transcript
Theravance Biopharma, Inc. (NASDAQ:TBPH) Q3 2024 Earnings Conference Call November 12, 2024 5:00 PM ETCompany ParticipantsRick Winningham - Chief Executive...- Published at
- by zacks.com
positivepositiveTheravance Biopharma (TBPH) Reports Q3 Loss, Tops Revenue Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of 40% and 4.71%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by gurufocus.com
positivepositiveTheravance Biopharma Q3 2024 Earnings: Revenue Surpasses Estimates at $16.87M, EPS Misses at -$0.26
Revenue: Reported $16.87 million for the third quarter, surpassing analyst estimates of $15.45 million.Net Loss: GAAP net loss of $12.70 million, compared to a- Published at
- by gurufocus.com
neutralneutralWhat To Expect From Theravance Biopharma Inc (TBPH) Q3 2024 Earnings
Theravance Biopharma Inc (TBPH) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $15.34 million, and the ea- Published at
- by gurufocus.com
positivepositiveSeth Klarman's Complete Exit from Theravance Biopharma Inc
Overview of the Recent Transaction On August 31, 2024, The Baupost Group, led by renowned value investor Seth Klarman (Trades, Portfolio), executed a significan- Published at
- by gurufocus.com
positivepositiveSeth Klarman's Strategic Reduction in Theravance Biopharma Inc
Overview of Recent Transaction On July 31, 2024, The Baupost Group, led by renowned value investor Seth Klarman (Trades, Portfolio), executed a significant redu- Published at
- by globenewswire.com
mixedmixedEnsho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
Portfolio of Oral Selective α4β7 Inhibitors Acquired from EA Pharma, Eisai’s GI Subsidiary Phase 2 Clinical Program in Ulcerative Colitis to Start in...